Copeptin and the S-100b Protein in Stroke

Vertigo, Peripheral Clinical Trial

Official title: Value of Copeptin and the S-100b Protein Assay in Ruling Out the Diagnosis of Stroke-induced Dizziness Pattern in Emergency Departments

Status Completed

Clinical Trial Summary

This study evaluated the value of using copetin and protein S 100 b to eliminate the diagnosis of stroke in patients presenting with vertigo in emergency departments. All patients benefited from the S 100b protein assay, copeptin and brain MRI.

Clinical Trial Description

Vertigo is a frequent reason for visiting emergency departments. Differentiating stroke from other causes is challenging for physicians. The role of biomarkers has been poorly assessed. Evaluators evaluated whether copeptin and S100b protein assessment, alone or in combination, could rule out stroke in patients visiting emergency departments for vertigo.

Evaluators included patients visiting the adult emergency departments of a French university hospital for a new episode of vertigo evolving for less than 72 hours. All patients underwent standardized physical examination (HINT [Head Impulse test, Nystagmus, test of skew deviation] maneuvers), copeptin and S-100b protein measurement and injected brain imaging. Stroke diagnosis involved diffusion-weighted magnetic resonance imaging or, if not available, neurological examination and contrast brain CT scan compatible with the diagnosis. ;

Related Conditions & MeSH terms

• Diabetes Insipidus
• Dizziness
• Vertigo
• Vertigo, Brain Stem
• Vertigo, Peripheral
• Vertigo; Central
• Vertigo; Cerebral

• NCT number: NCT03974464
• Study type: Observational
• Source: Poitiers University Hospital
• Status: Completed
• Start date: May 1, 2016
• Completion date: January 31, 2018